CD20 Antigen

• CD20 is a cell surface protein exclusively expressed on B lymphocytes from the pre-B cell stage through mature B cells.
• It is absent on hematopoietic stem cells, pro-B cells, and terminally differentiated plasma cells.
• The precise biological function of CD20 is not fully understood but is linked to B-cell activation and proliferation.
• CD20 serves as a crucial therapeutic target for monoclonal antibody therapies in conditions like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and certain autoimmune disorders.
• Targeting CD20 leads to the depletion of B cells, which can effectively treat diseases driven by B-cell dysfunction or malignancy.

What is CD20 Antigen?

CD20 antigen refers to a non-glycosylated phosphoprotein expressed on the surface of B lymphocytes, a type of white blood cell crucial for adaptive immunity. This protein is a member of the membrane-spanning 4A (MS4A) gene family and is characterized by four transmembrane domains, with both its N- and C-termini located within the cytoplasm. The expression of CD20 is highly specific to B cells, appearing early in B-cell development, specifically from the pre-B cell stage, and persisting through mature B cells. Notably, it is absent on very early progenitor B cells, hematopoietic stem cells, and terminally differentiated plasma cells, which are responsible for antibody production.

The consistent presence of CD20 on a broad range of B-cell developmental stages makes it an invaluable marker in immunology and clinical diagnostics. Its unique expression profile allows for the identification and enumeration of B cells in various tissues and blood samples, aiding in the diagnosis and classification of B-cell lymphomas and leukemias. Understanding the cellular distribution and structure of CD20 provides foundational insight into its biological significance and its utility as a therapeutic target.

Function and Clinical Role of CD20 Antigen

The precise CD20 antigen function is not entirely clear, but research suggests it plays a role in regulating B-cell activation, proliferation, and differentiation. It is thought to be involved in calcium channel activity and signal transduction pathways that are critical for B-cell survival and immune responses. While not directly involved in antigen recognition, CD20 appears to modulate the B-cell receptor (BCR) signaling, influencing how B cells respond to external stimuli and interact with other immune cells.

The significant CD20 antigen role in clinical medicine stems from its consistent expression on malignant B cells in various lymphomas and leukemias, as well as on pathogenic B cells in certain autoimmune diseases. This widespread expression makes CD20 an ideal target for therapeutic intervention using monoclonal antibodies. These antibodies, such as rituximab, bind specifically to the CD20 protein on the B-cell surface, triggering several mechanisms to eliminate these cells. These mechanisms include:

• Antibody-Dependent Cell-mediated Cytotoxicity (ADCC): Immune effector cells recognize the antibody-coated B cells and induce their destruction.
• Complement-Dependent Cytotoxicity (CDC): The binding of antibodies activates the complement system, leading to the lysis of B cells.
• Direct Apoptosis: Some anti-CD20 antibodies can directly induce programmed cell death in B cells.

This targeted depletion of B cells has revolutionized the treatment of conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and multiple sclerosis. By selectively removing CD20-positive B cells, these therapies can reduce tumor burden in cancers or dampen autoimmune responses, leading to improved patient outcomes. The ongoing development of new anti-CD20 antibodies and combination therapies continues to expand the clinical utility of targeting this pivotal B-cell antigen.